NA-Not Applicable; DOAC: direct oral anticoagulants; RE-LY: Randomized Evaluation of Long-Term Anticoagulation Therapy; ROCKET AF: Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; ENGAGE-TIMI 48: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48. This evidence concerns the gene F10 and atrial fibrillation.